Status:
ACTIVE_NOT_RECRUITING
Screening for Amyloidosis Before Aortic Valve Elective Replacement
Lead Sponsor:
Charite University, Berlin, Germany
Collaborating Sponsors:
Deutsches Herzzentrum Berlin, Klinik für Innere Medizin - Kardiologie
Klinik für Neurologie mit Experimenteller Neurologie, Charité - Universitätsmedizin Berlin
Conditions:
Amyloidosis
Aortic Valve Stenosis
Eligibility:
All Genders
40-99 years
Brief Summary
Previous studies detected that up to 15% of patients undergoing aortic valve replacement (AVR) for degenerative aortic stenosis have concomitant transthyretin amyloidosis (ATTR) cardiomyopathy (Castan...
Detailed Description
Untreated cardiac amyloidosis is accompanied with an impaired prognosis. Amyloidosis is often associated with ventricular hypertrophy which leads to severe heart failure and occurs frequently in conju...
Eligibility Criteria
Inclusion
- age ≥40 years
- written informed consent from the patient or of his/her legal guardian
- hospitalization for AVR due to degenerative aortic valve stenosis
Exclusion
- hemodynamically unstable patient
- severe co-morbidities with an estimated life expectancy of \<1 year
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2028
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04869631
Start Date
February 1 2021
End Date
March 31 2028
Last Update
February 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité - Universitätsmedizin Berlin
Berlin, Germany, 10117